Search Result

Isoforms Recommended:	MDM2 MDM2 MDM2

Results for "

MDM2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MDM-2/p53 (174) Akt (3) AMPK (1) Apoptosis (64) Autophagy (9) Bcl-2 Family (5) Biochemical Assay Reagents (1) c-Myc (5) Calcium Channel (1) Casein Kinase (5) Caspase (7) CCR (1) CDK (4) COX (2) CXCR (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (1) DAPK (1) Deubiquitinase (7) Dihydroorotate Dehydrogenase (3) DNA Methyltransferase (1) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Intermediate (2) Drug Isomer (4) Drug-Linker Conjugates for ADC (1) DYRK (1) E1/E2/E3 Enzyme (46) E3 Ligase Ligand-Linker Conjugates (6) Early 2 Factor (E2F) (1) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (3) Ferroptosis (1) Fluorescent Dye (1) Fungal (3) HDAC (3) Histone Methyltransferase (5) IAP (3) IFNAR (1) IGF-1R (1) IKZF Family (1) Integrin (1) Interleukin Related (2) IRAK (1) Isotope-Labeled Compounds (4) Ligands for E3 Ligase (8) Ligands for Target Protein for PROTAC (4) Lipoxygenase (1) LPL Receptor (1) MAGL (1) MAP4K (1) Molecular Glues (1) NF-κB (4) Notch (1) Parasite (1) PARP (4) PDK-1 (1) Pim (1) PROTACs (25) PTEN (1) Reactive Oxygen Species (ROS) (1) Reference Standards (6) RET (1) Sirtuin (3) Small Interfering RNA (siRNA) (3) STAT (1) Survivin (1) Target Protein Ligand-Linker Conjugates (10) TGF-beta/Smad (1) TNF Receptor (2) Topoisomerase (3) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (221) Cardiovascular Disease (2) Endocrinology (2) Infection (3) Inflammation/Immunology (11) Neurological Disease (9)
Click Chemistry:	PROTAC Synthesis (1) Azide (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

239

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: MDM-2/p53

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50696

Nutlin-3 40+ Cited Publications	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3 is a commercial available *p53-MDM2* inhibitor, with K_i of 90 nM.

HY-15676

Idasanutlin 50+ Cited Publications RG7388	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-152859

Brigimadlin BI 907828	E1/E2/E3 Enzyme MDM-2/p53	Cancer
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase *MDM-2* inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research ^[2] .

HY-10959

RG7112 20+ Cited Publications RO5045337	MDM-2/p53 E1/E2/E3 Enzyme	Neurological Disease Cancer
RG7112 is a potent, selective, orally active and blood-brain barrier crossed *MDM2-p53* inhibitor, with an IC₅₀ of 18 nM and a K_D of 11 nM for binding to MDM2 .

HY-12296

Navtemadlin 20+ Cited Publications AMG 232; KRT-232	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of *p53-MDM2* interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a K_d of 0.045 nM ^[2].

HY-101518

Alrizomadlin 4 Publications Verification APG-115; AA-115	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Alrizomadlin (APG-115) is an orally active *MDM2* protein inhibitor binding to MDM2 protein with IC₅₀ and K_i values of 3.8 nM and 1 nM, respectively . Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner ^[2] .

HY-170451

Seldegamadlin KT-253	PROTACs MDM-2/p53 Apoptosis	Cancer
Seldegamadlin (KT-253) is a selective p53 stabilizer and a MDM2 PROTAC degrader (DC₅₀ = 0.4 nM). Seldegamadlin inhibits the proliferation of cancer cell RS4;11 with an IC₅₀ of 0.3 nM, arrests the cell cycle at G2/M phase, and induces apoptosis. Seldegamadlin upregulates p53 activity and overcomes the p53-MDM2 feedback loop. Seldegamadlin can be used for the study of hematologic and solid tumors, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). (Pink: ligand for target protein MDM2 ligand 4 (HY-170452); Black: linker (HY-W001478); Blue: ligand for E3 ligase cereblon (HY-163927)) ^[2] .

HY-100892

MX69 2 Publications Verification	MDM-2/p53 IAP E1/E2/E3 Enzyme	Cancer
MX69 is an inhibitor of *MDM2/XIAP*, used for cancer treatment.

HY-18986

SAR405838 3 Publications Verification MI-77301	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity ^[2].

HY-128841

*PROTAC MDM2* Degrader-2** 1 Publications Verification	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-2 is an MDM2 PROTAC degrader. PROTAC MDM2 Degrader-2 can induce the self-ubiquitination and degradation of *MDM2, thereby upregulating the level of p53* protein. PROTAC MDM2 Degrader-2 has anti-tumor activity and can be used in the study of cancer . (Blue: MDM2 ligand (HY-128836); Black: linker (HY-128833))

HY-112816

MA242 1 Publications Verification	MDM-2/p53 Apoptosis	Cancer
MA242 is a specific dual inhibitor of *MDM2* and NFAT1. MA242 directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2. MA242 induces apoptosis in pancreatic cancer cell lines regardless of p53 status .

HY-128837

Nutlin carboxylic acid	Ligands for E3 Ligase Ligands for Target Protein for PROTAC	Cancer
Nutlin carboxylic acid is the Nutlin 3-based *MDM2* ligand. Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTAC .

HY-130684

MDM2 ligand 5	Ligands for E3 Ligase MDM-2/p53	Cancer
MDM2 ligand 5 is a Ligand for E3 Ligase that can be used for the synthesis of PROTACs .

HY-134823

MD-222 1 Publications Verification	MDM-2/p53 PROTACs E1/E2/E3 Enzyme	Cancer
MD-222 is the first-in-class highly potent PROTAC degrader of *MDM2. MD-222 consists of ligands for Cereblon* and *MDM2. MD-222 induces rapid degradation of the MDM2* protein and activation of wild-type p53 in cells. MD-222 has anticancer effects ^[2].

HY-15335

Nutlin-3b 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3b, the inactive form of Nutlin-3 (HY-50696), is a *p53/MDM2* inhibitor with an IC₅₀ of 13.6 μM. Nutlin-3b is 150 times less potent in binding to *MDM2* than Nutlin-3a (HY-10029). Nutlin-3b is promising for research of cancers ^[2] .

HY-110182

SP-141 4 Publications Verification	MDM-2/p53	Cancer
SP-141 is a specific inhibitor of *MDM2. SP-141 promotes MDM2* auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells .

HY-13423

Tenovin-1 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-1, a p53 activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a dihydroorotate dehydrogenase (DHODH) inhibitor ^[2].

HY-158684

YX-02-030	PROTACs MDM-2/p53 Apoptosis	Cancer
YX-02-030 is a VHL-dependent *MDM2* PROTAC degrader with a K_d of 35 nM. YX-02-030 recruits the VHL E3 ligase to form a ternary complex, leading to ubiquitination and proteasome-mediated degradation of MDM2. YX-02-030 inhibits MDM2-p53 and VHL-HIF1α binding with IC₅₀ values of 63 and 1350 nM. YX-02-030 activates TAp73, upregulates p53 family target genes and induces apoptosis. YX-02-030 demonstrates on-target efficacy in TNBC xenograft-bearing mice, extending survival without normal cell toxicity .

HY-153215

MEL24	Ligands for E3 Ligase	Cancer
MEL24 is an Mdm2 E3 ligase inhibitor that reduces cell survival and increases sensitivity to DNA damaging agents in a p53-dependent manner for in vitro antitumor studies .

HY-70027A

*p53 and MDM2* proteins-interaction-inhibitor dihydrochloride**	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-128832

Nutlin-C1-amido-PEG4-C2-N3 MDM2 Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 48	E3 Ligase Ligand-Linker Conjugates	Cancer
Nutlin-C1-amido-PEG4-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Nutlin 3 based MDM2 ligand and 4-unit PEG linker used in PROTAC technology. Nutlin-C1-amido-PEG4-C2-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-128840

*PROTAC MDM2* Degrader-1**	PROTACs MDM-2/p53	Cancer
PROTAC MDM2 Degrader-1 (Compound 15a) is a MDM2 PROTAC degrader. The structures of both Linker ends of PROTAC MDM2 Degrader-1 are MDM2 ligands. PROTAC MDM2 Degrader-1 can not only block the binding of p53-MDM2, but also degrade the target MDM2 protein by utilizing the function of the E3 ligase of MDM2 itself, thus exerting an anti-tumor effect. (Pink: MDM2 ligand 2 (HY-128836); Black: Linker (HY-128844); Blue: E3 ligase Ligand 15 (HY-128836))

HY-128842

*PROTAC MDM2* Degrader-3** 1 Publications Verification	PROTACs MDM-2/p53	Cancer
PROTAC MDM2 Degrader-3 is a *MDM2* self-degrading (dimeric) PROTAC. PROTAC MDM2 Degrader-3 can be used in cancer research .

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of *MDM2* and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-128843

*PROTAC MDM2* Degrader-4**	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-4 is a *MDM2* degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase .

HY-P1755

p53 (17-26)	MDM-2/p53	Cancer
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2*. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer ^[2].

HY-163357

*CDK2/MDM2-IN-1*	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-169240

MX69-102	MDM-2/p53	Cancer
MX69-102 (compound MX69-102) is an *MDM-2/p53* inhibitor, inducing *MDM2* degradation, resulting in p53 activation and cancer cell apoptosis. MX69-102 shows effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. .

HY-70027

*p53 and MDM2* proteins-interaction-inhibitor (chiral)**	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a *MDM2-p53* complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-RS08265

Mdm2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mdm2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mdm2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mdm2 Mouse Pre-designed siRNA Set A Mdm2 Mouse Pre-designed siRNA Set A

HY-15676A

Idasanutlin (enantiomer) RG7388 (enantiomer)	MDM-2/p53 Drug Isomer Apoptosis	Cancer
Idasanutlin enantiomer is the isomer of Idasanutlin (HY-15676), and can be used as an experimental control. Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-128836

(4R,5S)-Nutlin carboxylic acid	Ligands for E3 Ligase	Others
(4R,5S)-Nutlin carboxylic acid is a *MDM2* ligand and also a nutlin-3 derivative. (4R,5S)-Nutlin carboxylic acid can be linked to target protein ligands via a linker to form a PROTAC that can be used for targeting PARP1 .

HY-RS08264

MDM2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MDM2 Human Pre-designed siRNA Set A contains three designed siRNAs for MDM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MDM2 Human Pre-designed siRNA Set A MDM2 Human Pre-designed siRNA Set A

HY-W340839

*p53-MDM2-IN-1*	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-W340313

*p53-MDM2-IN-4*	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

HY-148106

MEL23	Ligands for E3 Ligase	Cancer
MEL23 is a MDM2 E3 ligase inhibitor that blocks the E3 ligase activity of the MDM2-MDMX complex. MEL23 inhibits Mdm2 and p53 ubiquitination in cells, reduce viability of cells with wild-type p53. MEL23 stabilizes MDM2 via a mechanism independent of p53 transcription .

HY-174458

MD-4251	PROTACs MDM-2/p53 IKZF Family Casein Kinase	Cancer
MD-4251 is an orally active *MDM2* PROTAC degrader. MD-4251 potently degrades MDM2 in RS4;11 cells (DC₅₀: 0.2 nM) and actives p53. MD-4251 shows strong antiproliferative activity against acute leukemia cells (wild-type p53) with minimal efficacy in mutant type. MD-4251 induces complete tumor regression in RS4;11 xenograft mice model . Pink: MDM2 ligand (HY-130684); Blue: CRBN ligase ligand (HY-W883326); Black: linker

HY-170452

MDM2 ligand 4	MDM-2/p53 Ligands for Target Protein for PROTAC	Cancer
MDM2 ligand 4 is the ligand for *MDM2* that can be used for synthesis of PROTAC degrader KT-253 (HY-170451) .

HY-123950

MMRi64	MDM-2/p53 Apoptosis	Cancer
MMRi64 disrupts *Mdm2-MdmX* interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .

HY-14967

NSC 66811 1 Publications Verification	MDM-2/p53	Cancer
NSC 66811 is a *MDM2-p53* inhibitor, with a K_i of 120 nM for binding to MDM2 .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an *MDM2*-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent *MDM2* inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .

HY-133760

MI-888	MDM-2/p53	Cancer
MI-888 is an orally active *MDM2* inhibitor with a K_i of 0.44 nM. MI-888 can inhibit the *MDM2-p53* interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity .

HY-124791

MMRi6	MDM-2/p53 PARP	Cancer
MMRi6 is a Mdm2-MdmX RING domain inhibitor that can disrupt Mdm2-MdmX RING-RING interaction in vitro. MMRi6 inhibits MdmX-stimulated *Mdm2* autoubiquitination and Mdm2-MdmX-mediated p53 polyubiquitination in vitro without affecting NEDD4-1 autoubiquitination. MMRi6 induces p53 stabilization and accumulation and induces PARP cleavage in wt-p53 Emu-myc lymphoma cells. MMRi6 inhibits the growth of wt-p53 and p53-null Emu-myc lymphoma cells with IC₅₀s of approximately 0.5 μM and 3 μM, respectively. MMRi6 can be used for the study of leukemia/lymphoma .

HY-RS08266

Mdm2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mdm2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mdm2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mdm2 Rat Pre-designed siRNA Set A Mdm2 Rat Pre-designed siRNA Set A

HY-70028

*p53 and MDM2* proteins-interaction-inhibitor (racemic)**	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-149250

*MDMX/MDM2-IN-2*	MDM-2/p53 Apoptosis	Cancer
MDMX/MDM2-IN-2 is a potent *p53-MDM2/MDMX* dual inhibitors with K_is of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .

HY-174266

WB156	MDM-2/p53	Cancer
WB156 is a dual *MDM2* and GSPT1 degrader. WB156 can recruit CRBN (Cereblon, a substrate receptor of the E3 ubiquitin-ligase complex) to induce the ubiquitination-proteasome pathway-mediated degradation of MDM2 and GSPT1. WB156 is promising for research of cancers, such as leukemia .

HY-150620

BI-0282	MDM-2/p53	Cancer
BI-0282 (Compound 1) is a potent *MDM2-p53* interaction inhibitor .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0068

Solasodine 5 Publications Verification Purapuridine; Solancarpidine; Solasodin	Infection Cardiovascular Disease Alkaloids Piperidine Alkaloids Neurological Disease Classification of Application Fields Solanum nigrum Linn. Solanaceae Plants Inflammation/Immunology Disease Research Fields Source Classification	MDM-2/p53 Fungal E1/E2/E3 Enzyme Apoptosis
Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine induces apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities ^[2] .

HY-N0894

Octahydrocurcumin 1 Publications Verification Hexahydrobisdemethoxycurcumin	Structural Classification Classification of Application Fields Other Diseases Phenols Polyphenols Plants Curcuma longa Disease Research Fields Source Classification Zingiberaceae	Apoptosis MAP4K NF-κB COX
Octahydrocurcumin (Hexahydrobisdemethoxycurcumin) is an orally active anticancer and anti-inflammatory agent, and is the final hydrogenated metabolite of Curcumin (HY-N0005) in vivo. Octahydrocurcumin exerts its anti-tumor and anti-inflammatory effects by inducing the mitochondrial apoptosis pathway and inhibiting the *TAK1-NF-κB-COX-2* pathway, respectively ^[2].

HY-N7012

7,3',4'-Tri-O-methylluteolin 1 Publications Verification 5-Hydroxy-3',4',7-trimethoxyflavone	Monophenols Flavonoids Classification of Application Fields Flavones Labiatae Phenols Plants Swartzia polyphylla DC. Inflammation/Immunology Disease Research Fields Source Classification	Lipoxygenase TNF Receptor Interleukin Related COX Fungal Parasite Apoptosis
7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone) is a flavonoid with multiple biological activities. 7,3',4'-Tri-O-methylluteolin inhibits soybean lipoxygenase (LOX), with an IC₅₀ value of 23.97 µg/mL. 7,3',4'-Tri-O-methylluteolin possesses anti-inflammatory effects in Lipopolysaccharides (HY-D1056) (LPS)-induced RAW 264.7 macrophages. 7,3',4'-Tri-O-methylluteolin inhibits the binding of MDM2 with p53 and induces apoptosis in MCF-7 breast cancer cells. 7,3',4'-Tri-O-methylluteolin also has antioxidant, antifungal and antitrypanosomal activities ^[2] sup>[4]sup>[5].

HY-N12768

Rhodojaponin VI	Structural Classification Terpenoids Diterpenoids Pieris japonica (Thunb.) D. Don ex G. Don Ericaceae Plants Source Classification	MDM-2/p53 Notch Calcium Channel
Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don (Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the *MDM2-Notch1* signalling pathway by reducing *MDM2* and Notch1 expression. Rhodojaponin VI indirectly reduces *Cav_2.2* current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain ^[2] .

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of *MDM2/p53*. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia ^[2].

HY-12296S

Navtemadlin-d7
Navtemadlin-d₇ is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM ^[2].

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity ^[2] .

HY-W704348

Diphenyltin Dichloride-d10
Diphenyltin Dichloride-d₁₀ is the deuterium labeled NSC405640 (HY-144105). NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks